Terms Of Terminally Disclaimed Patents Can Be Extended
Client Alert | 1 min read | 04.02.07
In Merck & Co. v. Hi-Tech Pharmacal Co., (No. 06-1156; March 29, 2007), a Federal Circuit panel affirms a district court’s judgment denying Hi-Tech’s motion to dismiss and holding that a patent term extension under § 156 may be applied to a patent subject to a terminal disclaimer.
Merck secured patent protection for the active ingredient in TRUSOPT® by filing a terminal disclaimer disavowing any term of the product patent that would extend beyond the expiry of an earlier Merck patent. Merck was then granted a patent term extension under 35 U.S.C. § 156 and that extension was based on the effective date of the terminal disclaimer, i.e., the expiry of the earlier Merck patent. Years later, Hi-Tech sought approval of a generic version of TRUSOPT®, asserting that the product patent had expired because the terminal disclaimer foreclosed the patent term extension. Hi-Tech moved to dismiss Merck’s claim for infringement and in response, Merck moved for judgment on the pleadings. The district court dismissed Hi-Tech’s motion, enjoining Hi-Tech from commercializing the drug claimed in the product patent until the end of the patent term extension. Hi-Tech appealed.
In affirming the district court’s decision, the Federal Circuit dismisses Hi-Tech’s argument that a terminal disclaimer is a waiver of patent term and the grant of an extension on such a patent improperly uncouples the extended patent and the earlier patent. The court noted that “[t]he purpose of the terminal disclaimer—to prevent extension of patent term for subject matter that would have been obvious over an earlier filed patent—remains fulfilled by virtue of the fact that the date from which any Hatch-Waxman extension is computed is the terminally disclaimed date. At the same time, the purpose of the patent term extension—to restore some of the patent term lost due to regulatory review—is also satisfied.”
Insights
Client Alert | 5 min read | 12.12.25
Eleventh Circuit Hears Argument on False Claims Act Qui Tam Constitutionality
On the morning of December 12, 2025, the Eleventh Circuit heard argument in United States ex rel. Zafirov v. Florida Medical Associates, LLC, et al., No. 24-13581 (11th Cir. 2025). This case concerns the constitutionality of the False Claims Act (FCA) qui tam provisions and a groundbreaking September 2024 opinion in which the United States District Court for the Middle District of Florida held that the FCA’s qui tam provisions were unconstitutional under Article II. See United States ex rel. Zafirov v. Fla. Med. Assocs., LLC, 751 F. Supp. 3d 1293 (M.D. Fla. 2024). That decision, penned by District Judge Kathryn Kimball Mizelle, was the first success story for a legal theory that has been gaining steam ever since Justices Thomas, Barrett, and Kavanaugh indicated they would be willing to consider arguments about the constitutionality of the qui tam provisions in U.S. ex rel. Polansky v. Exec. Health Res., 599 U.S. 419 (2023). In her opinion, Judge Mizelle held (1) qui tam relators are officers of the U.S. who must be appointed under the Appointments Clause; and (2) historical practice treating qui tam and similar relators as less than “officers” for constitutional purposes was not enough to save the qui tam provisions from the fundamental Article II infirmity the court identified. That ruling was appealed and, after full briefing, including by the government and a bevy of amici, the litigants stepped up to the plate this morning for oral argument.
Client Alert | 8 min read | 12.11.25
Director Squires Revamps the Workings of the U.S. Patent Office
Client Alert | 8 min read | 12.10.25
Creativity You Can Use: CJEU Clarifies Copyright for Applied Art
Client Alert | 4 min read | 12.10.25
Federal Court Strikes Down Interior Order Suspending Wind Energy Development
